Search

Your search keyword '"Nakamura, Ryotaro"' showing total 3 results
Start Over Author "Nakamura, Ryotaro" Topic hematopoietic stem cell transplantation Journal leukemia research
3 results on '"Nakamura, Ryotaro"'

1. Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.

Author

Ali H, Salhotra A, Stein AS, Nakamura R, Marcucci G, Forman SJ, Pullarkat V, and Aldoss I

Subjects
Adult, Aged, Allografts, Antibodies, Bispecific adverse effects, Female, Humans, Male, Middle Aged, Neoplasm, Residual, Antibodies, Bispecific administration & dosage, Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Published
2021
Full Text
View/download PDF

2. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

Author

Nakamura R, Gendzekhadze K, Palmer J, Tsai NC, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, and Stein A

Subjects
Adult, Aged, Aged, 80 and over, Cohort Studies, Cytomegalovirus Infections virology, Disease-Free Survival, Female, Genotype, Humans, Male, Middle Aged, Recurrence, Retrospective Studies, Risk Factors, Cytomegalovirus Infections complications, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Receptors, KIR genetics, Unrelated Donors, Virus Activation physiology
Abstract

Multiple retrospective studies have demonstrated an association between cytomegalovirus (CMV) reactivation and reduced risk of AML relapse. However, the potential mechanism explaining this association remains elusive. We investigated a homogeneous cohort of 288 adult patients with AML in remission who received allogeneic hematopoietic stem cell transplantation (HCT) from matched sibling/unrelated donors between 1995 and 2011. The 5-year cumulative incidence of relapse was greater in patients without CMV reactivation compared with those with reactivation (30.2% vs. 12.1%, p = 0.001) in a landmark analysis. In multivariate analyses CMV reactivation was independently associated with reduced relapse risk (HR: 0.49 [0.25-0.95], p = 0.036) and increased non-relapse mortality (26.5% vs. 13.1%, p = 0.002) resulting in similar 5-year overall survival (64.5% vs. 59.1%, p = 0.8). In further subgroup analyses the protective effect of CMV reactivation was significant in patients who received HCT from donors with KIR Bx compared to KIR AA (11.7% vs. 29.5%, p = 0.01). Likewise, the protective effect of CMV reactivation was more significant when the donors had 2DS1 activating KIR (11.5% vs. 30.7%, p = 0.05) compared with those without 2DS1 (14.3% vs. 27.5%, p = 0.12). Our data independently confirmed the association between CMV reactivation and AML relapse, suggesting the involvement of donor KIR genotypes and NK cell-mediated graft-versus-leukemia effect., (Copyright © 2019 Elsevier Ltd. All rights reserved.)

Published
2019
Full Text
View/download PDF

3. Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.

Author

Nakamura R, Palmer JM, O'Donnell MR, Stiller T, Thomas SH, Chao J, Alvarnas J, Parker PM, Pullarkat V, Maegawa R, Stein AS, Snyder DS, Bhatia R, Chang K, Wang S, Cai JL, Senitzer D, and Forman SJ

Subjects
Adult, Aged, Chemoprevention methods, Dose-Response Relationship, Drug, Drug Combinations, Female, Graft vs Host Disease epidemiology, Graft vs Host Disease etiology, Graft vs Host Disease mortality, Humans, Immunosuppressive Agents administration & dosage, Incidence, Male, Melphalan administration & dosage, Melphalan adverse effects, Middle Aged, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes mortality, Retrospective Studies, Survival Analysis, Transplantation, Homologous, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Young Adult, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Myelodysplastic Syndromes therapy, Sirolimus administration & dosage, Tacrolimus administration & dosage, Transplantation Conditioning methods
Abstract

We report a consecutive series of 59 patients with MDS who underwent reduced-intensity hematopoietic stem cell transplantation (RI-HSCT) with fludarabine/melphalan conditioning and tacrolimus/sirolimus-based GVHD prophylaxis. Two-year OS, EFS, and relapse incidences were 75.1%, 65.2%, and 20.9%, respectively. The cumulative incidence of non-relapse mortality at 100 days, 1 year, and 2 years was 3.4%, 8.5%, and 10.5%, respectively. The incidence of grade II-IV acute GVHD was 35.4%; grade III-IV was 18.6%. Forty of 55 evaluable patients developed chronic GVHD; of these 35 were extensive grade. This RI-HSCT protocol produces encouraging outcomes in MDS patients, and tacrolimus/sirolimus-based GVHD prophylaxis may contribute to that promising result., (Copyright © 2012 Elsevier Ltd. All rights reserved.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results